1. Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
- Author
-
Edwin Carter, David J. Webb, Nicholas L. Mills, James W. Dear, Robert Kimmitt, Tariq E. Farrah, Peter J. Gallacher, Neeraj Dhaun, and Atul Anand
- Subjects
Male ,030204 cardiovascular system & hematology ,Kidney ,Endothelins ,chemistry.chemical_compound ,0302 clinical medicine ,cardiovascular disease ,Medicine ,030212 general & internal medicine ,triglycerides ,Cross-Over Studies ,INSULIN SENSITIVITY ,CARDIOVASCULAR RISK ,ASSOCIATION ,Middle Aged ,3. Good health ,Proteinuria ,Treatment Outcome ,Cardiovascular Diseases ,SAFETY ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Female ,Proprotein Convertase 9 ,Endothelin receptor ,REDUCING LIPIDS ,Adult ,medicine.hormone ,medicine.medical_specialty ,Nifedipine ,Endothelin A Receptor Antagonists ,Risk Assessment ,Drug Administration Schedule ,ATRASENTAN ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,Internal Medicine ,Humans ,Renal Insufficiency, Chronic ,Aged ,Analysis of Variance ,Dose-Response Relationship, Drug ,business.industry ,Cholesterol ,EVOLOCUMAB ,PCSK9 ,cholesterol ,Cholesterol, LDL ,Original Articles ,EFFICACY ,medicine.disease ,REDUCTION ,Evolocumab ,Endocrinology ,chemistry ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,atherosclerosis ,LDL CHOLESTEROL ,endothelins ,business ,Antagonism ,Dyslipidemia ,Follow-Up Studies ,Kidney disease - Abstract
Supplemental Digital Content is available in the text., Dyslipidemia is common in chronic kidney disease (CKD). Despite statins, many patients fail to adequately lower lipids and remain at increased risk of cardiovascular disease. Selective ETA (endothelin-A) receptor antagonists reduce cardiovascular disease risk factors. Preclinical data suggest that ETA antagonism has beneficial effects on circulating lipids. We assessed the effects of selective ETA antagonism on circulating lipids and PCSK9 (proprotein convertase subtilisin/kexin type 9) in CKD. This was a secondary analysis of a fully randomized, double-blind, 3-phase crossover study. Twenty-seven subjects with predialysis CKD on optimal cardio- and renoprotective treatment were randomly assigned to receive 6 weeks dosing with placebo, the selective ETA receptor antagonist, sitaxentan, or long-acting nifedipine. We measured circulating lipids and PCSK9 at baseline and then after 3 and 6 weeks. Baseline lipids and PCSK9 did not differ before each study phase. Whereas placebo and nifedipine had no effect on lipids, 6 weeks of ETA antagonism significantly reduced total (−11±1%) and low-density lipoprotein–associated (−20±3%) cholesterol, lipoprotein (a) (−16±2%) and triglycerides (−20±4%); high-density lipoprotein–associated cholesterol increased (+14±2%), P
- Published
- 2019
- Full Text
- View/download PDF